MRNA vs MRNY: Which Is the Better Pick in 2026?

Overview

MRNA is Moderna Inc., a healthcare biotech stock trading at $63.32 with no dividend. MRNY is YieldMax MRNA Option Income Strategy ETF, an options-overlay fund that tracks Moderna synthetically through a covered-call strategy and distributes 73.62% annually in weekly payments. The key distinction: MRNA is direct equity ownership with no current income; MRNY wraps that same underlying in a mechanical income-generation structure that caps upside in exchange for yield.

How they differ

MRNA gives you the stock itself—you own Moderna's shares and participate fully in price appreciation or depreciation, with zero distributions. MRNY buys call options on MRNA to fund weekly income payments at a 73.62% distribution rate; in return, upside is capped at the strike prices YieldMax selects each week. The expense ratio difference is stark: MRNA incurs only a typical stock-trading cost, while MRNY charges 0.99% annually to manage the option overlay. MRNY's $117M AUM is tiny relative to MRNA's equity market cap, and the ETF's beta of 0.0 reflects its synthetic structure—it's insulated from broad market moves in ways the stock is not. Most critically, a 73.62% distribution yield invites NAV erosion unless Moderna's underlying stock returns match or exceed that payout; history suggests option-income strategies face principal leakage over multi-year periods.

Who each is best for

MRNA: Fits investors who believe in Moderna's long-term biotech pipeline and want full upside participation, with a time horizon long enough to tolerate healthcare-sector volatility and accept zero current income.

MRNY: Fits investors seeking regular weekly cash flow from Moderna exposure and willing to cap price appreciation in exchange for a high distribution rate, typically with shorter holding periods or a focus on current yield over total return.

Key risks to know

• NAV erosion at extreme yields. A 73.62% annualized distribution rate significantly exceeds the typical earnings or dividend yield of most equity holdings; sustaining this payout will likely require MRNY to return capital or draw on accumulated gains, eroding net asset value over time.

• Capped upside from covered-call overlay. MRNY's weekly call-selling mechanism caps gains at whatever strike YieldMax selects; if Moderna rallies sharply, MRNY holders forfeit upside while MRNA shareholders capture it.

• Options volatility and roll risk. The fund's income depends on the ability to sell new call contracts each week; if implied volatility collapses or Moderna's stock becomes less liquid, YieldMax may struggle to generate the same level of premium, reducing distributions.

• MRNA biotech and pipeline risk. Both securities are exposed to Moderna's clinical trial outcomes, regulatory decisions on its vaccine and therapeutic pipeline, and competitive pressures in the mRNA space. A major setback affects both instruments.

Bottom line

MRNA is for investors betting on Moderna's growth and willing to wait for potential appreciation; MRNY swaps that growth optionality for a steady stream of weekly income at the cost of capped upside and structural NAV decay. The choice hinges on whether you value long-term capital appreciation (MRNA) or near-term income with a shorter investment horizon (MRNY). Past performance of either instrument does not predict future results.